HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Internet Oversight “Ripe For Comment” In Free Speech Analysis – Lawyer

This article was originally published in The Rose Sheet

Executive Summary

FDA's regulation of claims made over the Internet is one aspect of policymaking that remains "ripe for comment" as the agency seeks public feedback on its regulatory decisions in light of recent First Amendment case law, Morgan Lewis partner Sandra Dennis opined

You may also be interested in...



FDA Commercial Speech Regs Constitutionality Debate Opened By Agency

FDA invites public comments on the constitutionality of its approach to regulating advertising and marketing practices for cosmetics, drugs and other products in a notice appearing in the May 16 Federal Register

Sunscreen, OTC Labeling Reg First Amendment Intrusions Cited By CTFA

FDA's sunscreen and OTC labeling final regs will have difficulty passing constitutional muster in light of a recent court decision requiring agency-drafted disclaimers for a folic acid health claim, the Cosmetic, Toiletry and Fragrance Association maintains.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Latest Headlines
See All
UsernamePublicRestriction

Register

RS010334

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel